<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35927763</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1741-7015</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>BMC medicine</Title><ISOAbbreviation>BMC Med</ISOAbbreviation></Journal><ArticleTitle>Medication use and risk of amyotrophic lateral sclerosis-a systematic review.</ArticleTitle><Pagination><StartPage>251</StartPage><MedlinePgn>251</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">251</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12916-022-02442-w</ELocationID><Abstract><AbstractText Label="BACKGROUND">Studying whether medications act as potential risk factors for amyotrophic lateral sclerosis (ALS) can contribute to the understanding of disease etiology as well as the identification of novel therapeutic targets. Therefore, we conducted a systematic review to summarize the existing evidence on the association between medication use and the subsequent ALS risk.</AbstractText><AbstractText Label="METHODS">A systematic review was conducted in Medline, Embase, and Web of Science from the date of database establishment to December 10, 2021. References of identified articles were further searched for additional relevant articles. Studies were included if (1) published in English, (2) explored medication use as exposure and development of ALS as outcome, and (3) the design was a human observational study. Clinical trials, reviews, comments, editorials, and case reports were excluded. Quality assessment was performed using a pre-validated tool for non-randomized studies, the Newcastle-Ottawa Assessment Scale (NOS).</AbstractText><AbstractText Label="RESULTS">Of the 4760 studies identified, 25 articles, including 13 case-control studies, five nested case-control studies, six cohort studies, and one retrospective chart review, were included in the review. Among these studies, there were 22 distinct study populations that included 171,407 patients with ALS, seven classes of medication examined, and 23 studies with a NOS&#x2009;&#x2265;&#x2009;5. There was a general lack of agreement between studies on the associations of cholesterol-lowering drugs, anti-inflammatory drugs, immunosuppressants, antibiotics, oral contraceptives (OCs) or hormone replacement therapy (HRT), antihypertensive drugs, antidiabetics, and drugs for psychiatric and neurological disorders with the subsequent risk of ALS. However, it appeared that statins, aspirin, OCs/HRT, antihypertensives, and antidiabetics were unlikely related to a higher risk of ALS. The positive associations noted for antibiotics, antidepressants, and skeletal muscle relaxants might be attributable to prodromal symptoms of ALS.</AbstractText><AbstractText Label="CONCLUSIONS">There is currently no strong evidence to link any medication use with ALS risk.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. cuican81818@outlook.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jiangwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKay</LastName><ForeName>Kyla A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Clinic, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. fang.fang@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 TS000324</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med</MedlineTA><NlmUniqueID>101190723</NlmUniqueID><ISSNLinking>1741-7015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Association</Keyword><Keyword MajorTopicYN="N">Medication</Keyword><Keyword MajorTopicYN="N">Risk</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>23</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35927763</ArticleId><ArticleId IdType="pmc">PMC9354307</ArticleId><ArticleId IdType="doi">10.1186/s12916-022-02442-w</ArticleId><ArticleId IdType="pii">10.1186/s12916-022-02442-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weil C, Zach N, Rishoni S, Shalev V, Chodick G. Epidemiology of amyotrophic lateral sclerosis: a population-based study in Israel. Neuroepidemiology. 2016;47(2):76&#x2013;81. doi: 10.1159/000448921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000448921</ArticleId><ArticleId IdType="pubmed">27617889</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoesmith CL, Strong MJ. Amyotrophic lateral sclerosis: update for family physicians. Can Fam Physician. 2006;52(12):1563&#x2013;1569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1783756</ArticleId><ArticleId IdType="pubmed">17279237</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32(5):771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Sel&#xe7;uk AA. A Guide for Systematic Reviews: PRISMA. Turk Arch Otorhinolaryngol. 2019;57(1):57&#x2013;58. doi: 10.5152/tao.2019.4058.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/tao.2019.4058</ArticleId><ArticleId IdType="pmc">PMC6461330</ArticleId><ArticleId IdType="pubmed">31049257</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA, Shea B, O&#x2019;Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale for theassessment of the quality of nonrandomized studies in metanalyses. 2009.</Citation></Reference><Reference><Citation>Pfeiffer RM, Mayer B, Kuncl RW, Check DP, Cahoon EK, Rivera DR, et al. Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(3&#x2013;4):235&#x2013;245. doi: 10.1080/21678421.2019.1682613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1682613</ArticleId><ArticleId IdType="pubmed">31684770</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;rensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3(4):413&#x2013;417. doi: 10.1161/CIRCOUTCOMES.110.936278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.110.936278</ArticleId><ArticleId IdType="pubmed">20530788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, Veldink JH, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatr. 2011;82(6):638&#x2013;642. doi: 10.1136/jnnp.2010.236752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.236752</ArticleId><ArticleId IdType="pubmed">21471184</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelen M, van Doormaal PT, Visser AE, Huisman MH, Roozekrans MH, de Jong SW, et al. Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol. 2014;261(10):1949&#x2013;1956. doi: 10.1007/s00415-014-7445-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7445-1</ArticleId><ArticleId IdType="pubmed">25059395</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman DM, Kuncl RW, Cahoon EK, Rivera DR, Pfeiffer RM. Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7&#x2013;8):538&#x2013;546. doi: 10.1080/21678421.2018.1511731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1511731</ArticleId><ArticleId IdType="pubmed">31112080</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer&#x2019;s and age-related neurodegenerative diseases. Alzheimers Dement (N Y) 2020;6(1):e12108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687291</ArticleId><ArticleId IdType="pubmed">33283039</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ronnevi LO, Almqvist C, Larsson H, et al. Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol. 2020;27(6):1010&#x2013;1016. doi: 10.1111/ene.14190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14190</ArticleId><ArticleId IdType="pubmed">32097525</ArticleId></ArticleIdList></Reference><Reference><Citation>Skajaa N, Bakos I, Horvath-Puho E, Henderson VW, Lash TL, Sorensen HT. Statin Initiation and risk of amyotrophic lateral sclerosis: a Danish population-based cohort study. Epidemiology. 2021;32(5):756&#x2013;762. doi: 10.1097/EDE.0000000000001384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000001384</ArticleId><ArticleId IdType="pubmed">34183532</ArticleId></ArticleIdList></Reference><Reference><Citation>Popat RA, Tanner CM, van den Eeden SK, Bernstein AL, Bloch DA, Leimpeter A, et al. Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8(3):157&#x2013;163. doi: 10.1080/17482960601179456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960601179456</ArticleId><ArticleId IdType="pubmed">17538777</ArticleId></ArticleIdList></Reference><Reference><Citation>Fondell E, O&#x2019;Reilly &#xc9;J, Fitzgerald KC, Falcone GJ, McCullough ML, Thun MJ, et al. Non-steroidal anti-inflammatory drugs and amyotrophic lateral sclerosis: results from five prospective cohort studies. Amyotroph Lateral Scler. 2012;13(6):573&#x2013;579. doi: 10.3109/17482968.2012.703209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.703209</ArticleId><ArticleId IdType="pmc">PMC3474335</ArticleId><ArticleId IdType="pubmed">22871075</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai CP, Lin FC, Lee JK, Lee CT. Aspirin use associated with amyotrophic lateral sclerosis: a total population-based case-control study. J Epidemiol. 2015;25(2):172&#x2013;177. doi: 10.2188/jea.JE20140070.</Citation><ArticleIdList><ArticleId IdType="doi">10.2188/jea.JE20140070</ArticleId><ArticleId IdType="pmc">PMC4310879</ArticleId><ArticleId IdType="pubmed">25721071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczmarski T, Stommel EW, Riley K, Tandan R, Chaudhry V, Clawson L, et al. Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS) J Neurol. 2017;264(8):1763&#x2013;1767. doi: 10.1007/s00415-017-8564-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8564-2</ArticleId><ArticleId IdType="pubmed">28711998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, et al. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2019;26(11):1355&#x2013;1361. doi: 10.1111/ene.13986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13986</ArticleId><ArticleId IdType="pubmed">31087715</ArticleId></ArticleIdList></Reference><Reference><Citation>Popat RA, Van Den Eeden SK, Tanner CM, Bernstein AL, Bloch DA, Leimpeter A, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis. Neuroepidemiology. 2006;27(3):117&#x2013;121. doi: 10.1159/000095550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000095550</ArticleId><ArticleId IdType="pubmed">16946622</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle P, Brown A, Beral V, Reeves G, Green J. Incidence of and risk factors for motor neurone disease in UK women: a prospective study. BMC Neurol. 2012;12:25. doi: 10.1186/1471-2377-12-25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-12-25</ArticleId><ArticleId IdType="pmc">PMC3512483</ArticleId><ArticleId IdType="pubmed">22559076</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney JPK, Visser AE, D&#x2019;Ovidio F, Vermeulen R, Beghi E, Chio A, et al. A case-control study of hormonal exposures as etiologic factors for ALS in women: Euro-MOTOR. Neurology. 2017;89(12):1283&#x2013;1290. doi: 10.1212/WNL.0000000000004390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004390</ArticleId><ArticleId IdType="pubmed">28835399</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekmann K, Kuzma-Kozakiewicz M, Piotrkiewicz M, Gromicho M, Grosskreutz J, Andersen PM, et al. Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. J Neurol. 2020;267(7):2130&#x2013;2141. doi: 10.1007/s00415-020-09799-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09799-z</ArticleId><ArticleId IdType="pubmed">32266542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YJ, Soto M, Branigan GL, Rodgers K, Brinton RD. Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy. Alzheimers Dement. 2021;7(1):e12174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8118114</ArticleId><ArticleId IdType="pubmed">34027024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin FC, Tsai CP, Kuang-Wu Lee J, Wu MT, Tzu-Chi LC. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol. 2015;72(1):40&#x2013;48. doi: 10.1001/jamaneurol.2014.3367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.3367</ArticleId><ArticleId IdType="pubmed">25383557</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchi C, Bianchi E, Pupillo E, Poloni M, Nobili A, Fortino I, et al. Angiotensin-converting enzyme inhibitors and motor neuron disease: An unconfirmed association. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(5&#x2013;6):385&#x2013;388. doi: 10.3109/21678421.2016.1143515.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1143515</ArticleId><ArticleId IdType="pubmed">26913547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cetin H, Sun J, Almqvist C, Reichardt B, Tomschik M, Zimprich F, et al. No association between proton pump inhibitor use and ALS risk: a nationwide nested case&#x2013;control study. Sci Rep. 2020;10(1):13371. doi: 10.1038/s41598-020-70373-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70373-8</ArticleId><ArticleId IdType="pmc">PMC7414209</ArticleId><ArticleId IdType="pubmed">32770128</ArticleId></ArticleIdList></Reference><Reference><Citation>Garwood ER, Bekele W, McCulloch CE, Christine CW. Amphetamine exposure is elevated in Parkinson&#x2019;s disease. Neurotoxicology. 2006;27(6):1003&#x2013;1006. doi: 10.1016/j.neuro.2006.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2006.03.015</ArticleId><ArticleId IdType="pubmed">16620991</ArticleId></ArticleIdList></Reference><Reference><Citation>Roos E, Mariosa D, Ingre C, Lundholm C, Wirdefeldt K, Roos PM, et al. Depression in amyotrophic lateral sclerosis. Neurology. 2016;86(24):2271&#x2013;2277. doi: 10.1212/WNL.0000000000002671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002671</ArticleId><ArticleId IdType="pmc">PMC4909561</ArticleId><ArticleId IdType="pubmed">27164661</ArticleId></ArticleIdList></Reference><Reference><Citation>Prosser JM, Fieve RR. Patients receiving lithium therapy have a reduced prevalence of neurological and cardiovascular disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2016;71:39&#x2013;44. doi: 10.1016/j.pnpbp.2016.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2016.06.006</ArticleId><ArticleId IdType="pubmed">27328427</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ovidio F, d&#x2019;Errico A, Farina E, Calvo A, Costa G, Chi&#xf2; A. Amyotrophic lateral sclerosis incidence and previous prescriptions of drugs for the nervous system. Neuroepidemiology. 2016;47(1):59&#x2013;66. doi: 10.1159/000448618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000448618</ArticleId><ArticleId IdType="pubmed">27561959</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet. 2019;28(4):688&#x2013;697. doi: 10.1093/hmg/ddy384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy384</ArticleId><ArticleId IdType="pmc">PMC6360326</ArticleId><ArticleId IdType="pubmed">30445611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol. 2019;85(4):470&#x2013;481. doi: 10.1002/ana.25431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25431</ArticleId><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S, et al. Statins and the brain: more than lipid lowering agents? Curr Neuropharmacol. 2019;17(1):59&#x2013;83. doi: 10.2174/1570159X15666170703101816.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X15666170703101816</ArticleId><ArticleId IdType="pmc">PMC6341496</ArticleId><ArticleId IdType="pubmed">28676012</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Segura LM, Balthazart J. Steroids and neuroprotection: new advances. Front Neuroendocrinol. 2009;30(2):v&#x2013;ix. doi: 10.1016/j.yfrne.2009.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2009.04.006</ArticleId><ArticleId IdType="pmc">PMC3522859</ArticleId><ArticleId IdType="pubmed">19393683</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M, Kelley MH, Herson PS, Hurn PD. Neuroprotection of sex steroids. Minerva Endocrinol. 2010;35(2):127&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3036837</ArticleId><ArticleId IdType="pubmed">20595940</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbiati M, Onesto E, Zito A, Crippa V, Rusmini P, Mariotti R, et al. The anabolic/androgenic steroid nandrolone exacerbates gene expression modifications induced by mutant SOD1 in muscles of mice models of amyotrophic lateral sclerosis. Pharmacol Res. 2012;65(2):221&#x2013;230. doi: 10.1016/j.phrs.2011.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2011.12.001</ArticleId><ArticleId IdType="pmc">PMC3272141</ArticleId><ArticleId IdType="pubmed">22178654</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciriaco M, Ventrice P, Russo G, Scicchitano M, Mazzitello G, Scicchitano F, et al. Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother. 2013;4(Suppl 1):S94&#x2013;S98. doi: 10.4103/0976-500X.120975.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0976-500X.120975</ArticleId><ArticleId IdType="pmc">PMC3853679</ArticleId><ArticleId IdType="pubmed">24347992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassa RM, Bonafede R, Boschi F, Bentivoglio M, Mariotti R. Effect of physical exercise and anabolic steroid treatment on spinal motoneurons and surrounding glia of wild-type and ALS mice. Brain Res. 2017;1657:269&#x2013;278. doi: 10.1016/j.brainres.2016.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.12.029</ArticleId><ArticleId IdType="pubmed">28048973</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JH, Lee YA, Lee JK, Lee YB, Cho W, Im DS, et al. Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012;122(5):952&#x2013;961. doi: 10.1111/j.1471-4159.2012.07771.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2012.07771.x</ArticleId><ArticleId IdType="pubmed">22537108</ArticleId></ArticleIdList></Reference><Reference><Citation>Werdelin L, Boysen G, Jensen TS, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 1990;82(2):132&#x2013;134. doi: 10.1111/j.1600-0404.1990.tb01602.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1990.tb01602.x</ArticleId><ArticleId IdType="pubmed">2256442</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, et al. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3&#x2013;4):242&#x2013;249. doi: 10.1080/21678421.2017.1421666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1421666</ArticleId><ArticleId IdType="pubmed">29308669</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474&#x2013;480. doi: 10.1038/s41586-019-1443-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1443-5</ArticleId><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrenovich M, Jaworski H, Tadimalla T, Mistry A, Sykes L, Perry G, et al. The role of the microbiota-gut-brain axis and antibiotics in ALS and neurodegenerative diseases. Microorganisms. 2020;8(5):784. doi: 10.3390/microorganisms8050784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms8050784</ArticleId><ArticleId IdType="pmc">PMC7285349</ArticleId><ArticleId IdType="pubmed">32456229</ArticleId></ArticleIdList></Reference><Reference><Citation>Shortridge E, Miller K. Contraindications to oral contraceptive use among women in the United States, 1999&#x2013;2001. Contraception. 2007;75(5):355&#x2013;360. doi: 10.1016/j.contraception.2006.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.contraception.2006.12.022</ArticleId><ArticleId IdType="pubmed">17434016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannaford PC, Kay CR. The risk of serious illness among oral contraceptive users: evidence from the RCGP&#x2019;s oral contraceptive study. Br J Gen Pract. 1998;48(435):1657&#x2013;1662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1313240</ArticleId><ArticleId IdType="pubmed">10071398</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A, Smith JA, Gibson C, Varma AK, Ray SK, Banik NL. Estrogen receptor agonists and estrogen attenuate TNF-&#x3b1;-induced apoptosis in VSC4.1 motoneurons. J Endocrinol. 2011;208(2):171&#x2013;82. doi: 10.1677/JOE-10-0338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/JOE-10-0338</ArticleId><ArticleId IdType="pmc">PMC3951893</ArticleId><ArticleId IdType="pubmed">21068071</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardona-Rossinyol A, Mir M, Caraballo-Miralles V, Llad&#xf3; J, Olmos G. Neuroprotective effects of estradiol on motoneurons in a model of rat spinal cord embryonic explants. Cell Mol Neurobiol. 2013;33(3):421&#x2013;432. doi: 10.1007/s10571-013-9908-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-013-9908-9</ArticleId><ArticleId IdType="pubmed">23322321</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Kamel F, Bellocco R, Ye W, Fang F. Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 2015;22(11):1436&#x2013;1442. doi: 10.1111/ene.12632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12632</ArticleId><ArticleId IdType="pmc">PMC4506907</ArticleId><ArticleId IdType="pubmed">25600257</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng P, Wang T, Zheng J, Zhou X. Causal association of type 2 diabetes with amyotrophic lateral sclerosis: new evidence from Mendelian randomization using GWAS summary statistics. BMC Med. 2019;17(1):225. doi: 10.1186/s12916-019-1448-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-019-1448-9</ArticleId><ArticleId IdType="pmc">PMC6892209</ArticleId><ArticleId IdType="pubmed">31796040</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;tz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Sch&#xfc;rmann B, et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci. 2005;25(34):7805&#x2013;7812. doi: 10.1523/JNEUROSCI.2038-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2038-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725264</ArticleId><ArticleId IdType="pubmed">16120782</ArticleId></ArticleIdList></Reference><Reference><Citation>Schijven D, Stevelink R, McCormack M, van Rheenen W, Luykx JJ, Koeleman BPC, et al. Analysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy. Neurobiol Aging. 2020;92:153.e1&#x2013;.e5. doi: 10.1016/j.neurobiolaging.2020.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.04.011</ArticleId><ArticleId IdType="pmc">PMC7818383</ArticleId><ArticleId IdType="pubmed">32409253</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang J, Chao D, Sandhu HK, Yu Y, Zhang L, Balboni G, et al. &#x3b4;-Opioid receptors up-regulate excitatory amino acid transporters in mouse astrocytes. Br J Pharmacol. 2014;171(23):5417&#x2013;5430. doi: 10.1111/bph.12857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12857</ArticleId><ArticleId IdType="pmc">PMC4294049</ArticleId><ArticleId IdType="pubmed">25052197</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornai F, Longone P, Ferrucci M, Lenzi P, Isidoro C, Ruggieri S, et al. Autophagy and amyotrophic lateral sclerosis: the multiple roles of lithium. Autophagy. 2008;4(4):527&#x2013;530. doi: 10.4161/auto.5923.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.5923</ArticleId><ArticleId IdType="pubmed">18367867</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89(18):1915&#x2013;1922. doi: 10.1212/WNL.0000000000004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS) Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):453&#x2013;456. doi: 10.3109/21678421.2014.903974.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903974</ArticleId><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrandell-Haro G, Branigan GL, Vitali F, Geifman N, Zissimopoulos JM, Brinton RD. Statin therapy and risk of Alzheimer&#x2019;s and age-related neurodegenerative diseases. Alzheimers Dement (N Y) 2020;6(1):e12108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7687291</ArticleId><ArticleId IdType="pubmed">33283039</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada-Ramallal G, Takkouche B, Figueiras A. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review. BMC Med Res Methodol. 2019;19(1):53. doi: 10.1186/s12874-019-0695-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-019-0695-y</ArticleId><ArticleId IdType="pmc">PMC6419460</ArticleId><ArticleId IdType="pubmed">30871502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise L. Risks and benefits of (pharmaco)epidemiology. Ther Adv Drug Saf. 2011;2(3):95&#x2013;102. doi: 10.1177/2042098611404920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042098611404920</ArticleId><ArticleId IdType="pmc">PMC4110815</ArticleId><ArticleId IdType="pubmed">25083205</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Sujan AC, Butwicka A, Chang Z, Cortese S, Quinn P, et al. Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review. CNS Drugs. 2020;34(7):731&#x2013;747. doi: 10.1007/s40263-020-00728-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-020-00728-2</ArticleId><ArticleId IdType="pmc">PMC7338246</ArticleId><ArticleId IdType="pubmed">32333292</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta R, D&#x2019;Ovidio F, Logroscino G, Chi&#xf2; A. The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurol Sci. 2021;42(4):1377&#x2013;1387. doi: 10.1007/s10072-021-05099-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05099-0</ArticleId><ArticleId IdType="pmc">PMC7955983</ArticleId><ArticleId IdType="pubmed">33544228</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Sveinsson O, Press R, Ye W, Ingre C, Piehl F, Fang F. ALS patients with concurrent neuroinflammatory disorders; a nationwide clinical records study. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(3-4):209&#x2013;19. 10.1080/21678421.2021.1946084. Epub 2021 Jul 10. PMID: 34852680.</Citation><ArticleIdList><ArticleId IdType="pubmed">34852680</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Tian L, Cai T, Claggett B, Wei LJ. Effectively selecting a target population for a future comparative study. J Am Stat Assoc. 2013;108(502):527&#x2013;539. doi: 10.1080/01621459.2013.770705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.2013.770705</ArticleId><ArticleId IdType="pmc">PMC3775385</ArticleId><ArticleId IdType="pubmed">24058223</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11(7):437&#x2013;441. doi: 10.1038/nrrheum.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.30</ArticleId><ArticleId IdType="pmc">PMC4486631</ArticleId><ArticleId IdType="pubmed">25800216</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399&#x2013;424. doi: 10.1080/00273171.2011.568786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Admon AJ, Donnelly JP, Casey JD, Janz DR, Russell DW, Joffe AM, et al. Emulating a novel clinical trial using existing observational data. Predicting results of the PreVent study. Ann Am Thorac Soc. 2019;16(8):998&#x2013;1007. doi: 10.1513/AnnalsATS.201903-241OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.201903-241OC</ArticleId><ArticleId IdType="pmc">PMC6774748</ArticleId><ArticleId IdType="pubmed">31038996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9(4):223&#x2013;228. doi: 10.1080/17482960802031092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802031092</ArticleId><ArticleId IdType="pubmed">18608105</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Sheng L, Shang H. Statins and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(4):241&#x2013;245. doi: 10.3109/21678421.2012.732078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.732078</ArticleId><ArticleId IdType="pubmed">23134508</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi M, Shui A, Dibernardo AB, Brown RH, Jr, Schoenfeld DA, Cudkowicz ME. Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9(6):369&#x2013;374. doi: 10.1080/17482960802163614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802163614</ArticleId><ArticleId IdType="pubmed">18608098</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, et al. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS ONE. 2012;7(6):e37885. doi: 10.1371/journal.pone.0037885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037885</ArticleId><ArticleId IdType="pmc">PMC3371007</ArticleId><ArticleId IdType="pubmed">22715372</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>